<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Posttransplantation diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Posttransplantation diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Posttransplantation diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodolfo J Galindo, MD, FACE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Asif Sharfuddin, MD, FASN, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brent W Miller, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2410959185"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diabetes is a common complication following kidney transplantation. Posttransplantation diabetes mellitus (PTDM) is associated with increased mortality and morbidity and, in particular, higher rates of cardiovascular disease and infection, which are the leading causes of death in kidney transplant recipients.</p><p>This topic reviews the epidemiology, risk factors, and clinical implications of PTDM, as well as recommendations for screening and treatment. Issues relating to kidney transplantation and combined kidney-pancreas transplantation in patients with preexisting diabetes are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7349.html" rel="external">"Kidney transplantation in diabetic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7313.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Benefits and complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7305.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Patient selection and pretransplant evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H1770040245"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttransplantation diabetes mellitus (PTDM)</strong> – PTDM describes the presence of diabetes after transplantation, irrespective of timing of diagnosis or whether it was present but undetected before transplantation. We and others [<a href="#rid1">1</a>] prefer this term over new-onset diabetes after transplantation (NODAT) because NODAT does not include patients who may have had diabetes prior to transplant that was unrecognized. However, we prefer to differentiate diabetes that was undiagnosed during the pretransplant period (typically type 2 diabetes) from diabetes that develops in the posttransplant period, given the differences in the pathophysiology of these conditions [<a href="#rid2">2-5</a>]. Importantly, the term PTDM <strong>excludes</strong> patients with transient posttransplant hyperglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>New-onset diabetes mellitus after transplantation (NODAT)</strong> – This term was established by an international consensus guideline in 2003 to describe the pathophysiological consequences of transplantation on glucose metabolism [<a href="#rid6">6</a>]. The guidelines recommended that the definition and diagnosis of NODAT be based upon the standard World Health Organization (WHO) and American Diabetes Association (ADA) criteria for the diagnosis of diabetes mellitus and impaired glucose tolerance  (<a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef82479" href="/z/d/graphic/82479.html" rel="external">table 2</a>) [<a href="#rid7">7,8</a>]. By definition, the term NODAT does not include patients who may have had diabetes prior to transplant that was unrecognized. Many transplant centers do not screen for undiagnosed diabetes during the pretransplant evaluation, so pretransplant diabetes is not accurately identified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient posttransplant hyperglycemia</strong> – This term refers to transient hyperglycemia that occurs in the immediate-to-early posttransplant setting, generally as a result of postsurgical stress or with the administration of high-dose glucocorticoids  (<a class="graphic graphic_figure graphicRef127089" href="/z/d/graphic/127089.html" rel="external">figure 1</a>) [<a href="#rid9">9</a>]. In most cases, posttransplant hyperglycemia is transient and resolves within the first few weeks after transplantation. Transient hyperglycemia may also occur later posttransplant in the setting of acute infection or treatment of rejection. Such patients should <strong>not</strong> be diagnosed with PTDM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other terms</strong> – Terms in use following the initial recognition of hyperglycemia after kidney transplantation in 1964 [<a href="#rid10">10</a>] include posttransplantation hyperglycemia and diabetes after transplantation [<a href="#rid2">2</a>]. However, these terms are generally not used.</p><p></p><p class="headingAnchor" id="H1788164592"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The reported incidence of posttransplantation diabetes mellitus (PTDM) is variable and must be interpreted in the context of definition used, time from transplant, study population, and immunosuppressive agents used for individual studies. Studies that were published prior to the development of the 2003 consensus definition for new-onset diabetes after transplantation (NODAT) described above reported rates ranging from 7 to 46 percent [<a href="#rid11">11-14</a>]. (See <a class="local">'Terminology'</a> above.)</p><p>Several studies have provided incidence estimates of NODAT defined by the 2003 international consensus guidelines, including the use of the oral glucose tolerance test (OGTT) [<a href="#rid15">15-19</a>]. A substantial number of patients who were classified as having PTDM in these reports became normoglycemic without any medical therapy, suggesting that their hyperglycemia was transient and that incidence was overestimated in these reports. However, even transient perioperative hyperglycemia may suggest a higher risk for the future development of PTDM (see <a class="local">'Modifiable risk factors'</a> below). Overall, studies that use the existing criteria for diagnosis suggest that up to one-third of nondiabetic kidney transplant recipients develop prediabetes or PTDM by six months posttransplantation [<a href="#rid15">15,16,19,20</a>].</p><p>Although earlier reports suggested an increasing incidence of PTDM [<a href="#rid14">14</a>], subsequent data from the Organ Procurement and Transplant Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) showed that the prevalence of PTDM at one year posttransplant decreased from 10 percent in 2007 to under 4 percent in 2016, while the five-year incidence of PTDM decreased from approximately 16 percent in 2007 to 10 percent in 2012 [<a href="#rid21">21,22</a>]. Long-term studies have reported two- to five-year incidence rates ranging from 18 to 33 percent [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H3722616050"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H2177681757"><span class="h2">Modifiable risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive agents</strong> – Immunosuppressive agents that contribute to posttransplantation diabetes mellitus (PTDM) include glucocorticoids, calcineurin inhibitors, and mammalian (mechanistic) target of rapamycin (mTOR) inhibitors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – Higher doses of glucocorticoids among kidney transplant patients have been associated with the development of PTDM [<a href="#rid11">11,22,25-27</a>]. In one study of 173 patients, for example, there was a significant relationship between <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> dose and two-hour serum glucose levels measured for oral glucose tolerance tests (OGTTs) [<a href="#rid25">25</a>]. The risk of developing PTDM was 5 percent per 0.01 mg/kg per day increase in prednisolone dose. The progressive reduction in daily glucocorticoid dose may explain the significantly lower rates of PTDM compared with those reported several decades ago (46 percent in 1979) [<a href="#rid11">11,22,25-27</a>].</p><p></p><p class="bulletIndent2">However, complete glucocorticoid withdrawal has not been clearly shown to reduce the incidence of PTDM, as studies comparing glucocorticoid withdrawal with glucocorticoid continuation have not produced consistent results [<a href="#rid28">28-31</a>]. A significant percentage of patients suffer an episode of acute rejection following glucocorticoid withdrawal, requiring reinstitution of glucocorticoid therapy, often with high doses; pulsed, high-dose glucocorticoid therapy for acute rejection increased the risk for PTDM [<a href="#rid32">32</a>]. Thus, adjustment of immunosuppression therapy aimed at improving glucose tolerance must be weighed against the risk of allograft rejection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcineurin inhibitors</strong> – Both <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> increase the risk of PTDM [<a href="#rid33">33</a>]. Tacrolimus is more diabetogenic than cyclosporine [<a href="#rid12">12,13,17,18,23,34-41</a>]. Increased tacrolimus levels have strong associations with impaired glucose tolerance and PTDM. In one study, levels higher than 15 ng/mL were significantly associated with the development of glucose intolerance and PTDM at one year [<a href="#rid42">42</a>]. Incidence rates of PTDM appear to be similar between extended-release versus immediate-release tacrolimus formulations [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2">Both calcineurin inhibitors cause reversible toxicity to islet cells and may directly affect transcriptional regulation of insulin expression [<a href="#rid44">44,45</a>]. Some evidence suggests <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> causes more severe swelling and vacuolization of islet cells [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>mTOR inhibitors</strong> – <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is diabetogenic [<a href="#rid17">17,47</a>]. Conversion to sirolimus from <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> has been associated with a significant worsening of rather than an improvement in insulin resistance. The incidence of PTDM appears to be similar between a sirolimus- and everolimus-based regimen and between early and late conversion from a calcineurin inhibitor to an mTOR inhibitor [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents</strong> – <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), and <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> do not have independent diabetogenic effects. In one large, retrospective study, the use of azathioprine and MMF was associated with a decreased risk of PTDM (relative risk [RR] 0.84, 95% CI 0.72-0.97 and 0.78, 95% CI 0.69-0.88, respectively) [<a href="#rid13">13</a>]. This benefit may be explained by the use of lower doses of glucocorticoids with these drugs, although this is unproven.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative impaired glucose tolerance and perioperative hyperglycemia</strong> – Preoperative impaired glucose tolerance identifies transplant candidates who are at higher risk for the development of PTDM. In one study of 120 nondiabetic transplant recipients, an OGTT diagnosed impaired glucose tolerance in 18 percent of patients prior to transplantation [<a href="#rid49">49</a>]. Among 31 patients who developed PTDM, 11 (35 percent) had impaired glucose tolerance pretransplant. Multivariate analysis identified pretransplant impaired glucose tolerance as a risk factor for the development of PTDM (RR 2.4, 95% CI 1.1-5.3). Other studies that have examined the incidence of impaired glucose tolerance and PTDM using serial posttransplant OGTTs suggest that the majority of patients developing persistent PTDM can be identified within three months of transplantation and, conversely, that patients with a normal OGTT 3 to 12 months posttransplant are at low risk for developing late PTDM [<a href="#rid16">16,50</a>].</p><p></p><p class="bulletIndent1">Perioperative hyperglycemia is also associated with the development of PTDM [<a href="#rid17">17,51</a>]. In one retrospective study, among 349 patients who developed hyperglycemia during the transplantation hospitalization, 102 (29 percent) developed PTDM within the first year after transplantation [<a href="#rid51">51</a>]. By contrast, only 1 of 28 patients (4 percent) who did not have perioperative hyperglycemia developed PTDM. The risk of PTDM was highest among patients who required insulin. Although the incidence and relevance of perioperative hyperglycemia depend upon specific center immunosuppressive protocols (eg, glucocorticoid administration), perioperative hyperglycemia may allow the identification of patients at increased risk for PTDM [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – Several studies have found an association between obesity (body mass index of ≥30 kg/m<sup>2</sup>) and increased risk of PTDM [<a href="#rid13">13,33,34,36,42,50,53-55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Hepatitis C virus (HCV) infection correlates with both pre- and posttransplant diabetes [<a href="#rid13">13,34-36,56-59</a>]. A meta-analysis of 10 studies involving 2502 kidney transplant recipients found that HCV-positive patients, compared with uninfected individuals, were nearly four times more likely to have PTDM [<a href="#rid58">58</a>]. Proposed mechanisms for HCV-induced PTDM include HCV-induced islet cell dysfunction and insulin resistance due to liver dysfunction [<a href="#rid60">60</a>]. HCV infection is a potentially modifiable risk factor for PTDM as treatment prior to transplantation may decrease the incidence of PTDM [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">Cytomegalovirus (CMV) infection has also been reported to increase the risk of PTDM [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomagnesemia</strong> – Low magnesium levels have been associated with insulin resistance and diabetes in nontransplant patients [<a href="#rid64">64-67</a>]. However, studies evaluating the association between serum magnesium levels and the development of PTDM have shown conflicting results [<a href="#rid68">68-73</a>]. (See  <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">"Type 2 diabetes mellitus: Prevalence and risk factors", section on 'Other'</a>.)</p><p></p><p class="headingAnchor" id="H2259085470"><span class="h2">Nonmodifiable risk factors</span><span class="headingEndMark"> — </span>Nonmodifiable risk factors for PTDM include the following [<a href="#rid6">6,13,25,34,50,53,74-76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased age (≥40 to 45 years)</p><p class="bulletIndent1"><span class="glyph">●</span>African American race</p><p class="bulletIndent1"><span class="glyph">●</span>Hispanic ethnicity</p><p class="bulletIndent1"><span class="glyph">●</span>History of gestational diabetes or first-degree family history of type 2 diabetes</p><p class="bulletIndent1"><span class="glyph">●</span>Increased human leukocyte antigen (HLA) mismatching</p><p class="bulletIndent1"><span class="glyph">●</span>Male and deceased-donor allografts</p><p></p><p>Polycystic kidney disease may confer an increased risk of PTDM, although this has not been consistently observed [<a href="#rid36">36,77-82</a>].</p><p class="headingAnchor" id="H2198649823"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Genetic factors may also contribute to the risk of developing PTDM after kidney transplantation [<a href="#rid83">83-85</a>]. Several different genes have been studied in various populations, but the results of these studies are inconclusive and differ among populations. While the identification of genetic factors that predispose patients to PTDM may aid in deciding the proper immunosuppressive therapy in patients with an increased risk of PTDM, routine genetic testing is not recommended.</p><p class="headingAnchor" id="H1554574461"><span class="h1">EVALUATION AND DIAGNOSIS OF PTDM</span></p><p class="headingAnchor" id="H3895370990"><span class="h2">Evaluation for PTDM</span><span class="headingEndMark"> — </span>All kidney transplant recipients, whether or not they have a pre-identified increased risk, should be routinely evaluated for posttransplant diabetes mellitus (PTDM) after transplantation:</p><p class="bulletIndent1"><span class="glyph">●</span>We measure a fasting plasma glucose level weekly during the first four weeks posttransplant after hospital discharge, then at three and six months posttransplant, and then yearly thereafter.</p><p></p><p class="bulletIndent1">Some centers evaluate for PTDM with an afternoon capillary blood glucose level, rather than a fasting plasma glucose, in the first few weeks posttransplant. This is based on one observational study that showed that afternoon (ie, 4:00 PM) capillary glucose levels ≥200 mg/dL [11.1 mmol/L] were more sensitive than fasting plasma glucose levels, glycated hemoglobin (A1C), and oral glucose tolerance tests (OGTTs) at detecting PTDM within the first six weeks after transplantation (46 versus 0, 4, and 12 percent, respectively) [<a href="#rid86">86</a>]. However, this approach has not yet been validated for the diagnosis of PTDM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An A1C can be checked after three months posttransplant, particularly if it is difficult to obtain fasting plasma glucose levels [<a href="#rid1">1,87</a>]. We typically check an A1C at 3, 6, and 12 months posttransplant and then yearly thereafter in patients who have not developed PTDM. A1C should not be used to evaluate for PTDM prior to three months posttransplant, since a normal test cannot exclude the diagnosis in the setting of posttransplant anemia, recovery from pretransplant anemia, or dynamic kidney allograft function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do <strong>not</strong> routinely perform OGTT to evaluate for PTDM. Although this test is considered the gold standard for the diagnosis of PTDM, its use is limited by inconvenience and cost.</p><p></p><p>Criteria for the diagnosis of PTDM are presented below. (See <a class="local">'Establishing the diagnosis'</a> below.)</p><p class="headingAnchor" id="H1792942842"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of posttransplant diabetes mellitus (PTDM) should ideally be made when patients are stable on their maintenance immunosuppression regimen, with stable kidney allograft function and in the absence of acute infection [<a href="#rid1">1</a>]. Transient, posttransplant hyperglycemia (see <a class="local">'Terminology'</a> above) is very common (up to 90 percent of patients) in the immediate-to-early posttransplant period but usually resolves within the first few weeks after transplantation. Thus, to avoid labeling the majority of kidney transplant recipients with PTDM in the immediate-to-early posttransplant period, a formal diagnosis of PTDM should <strong>not </strong>be made in patients within the first six weeks after transplantation [<a href="#rid1">1</a>]. However, if the patient fulfills diagnostic criteria for PTDM beyond six weeks posttransplantation, a formal diagnosis of PTDM is made.</p><p>PTDM may be diagnosed after transplantation by any of the following, all of which are the same as diagnostic criteria for nontransplant patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of diabetes plus random plasma glucose ≥200 mg/dL (11.1 mmol/L). Symptoms include polyuria, polydipsia, and unexplained weight loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least eight hours. An abnormal fasting blood glucose should be confirmed on another day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as described by the World Health Organization (WHO), using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A1C ≥6.5 percent, three or more months posttransplant. The A1C is <strong>not</strong> recommended for diagnosis during the first three months after transplantation [<a href="#rid86">86</a>], because the test may not be valid until new hemoglobin has been synthesized and glycated for the appropriate period in the diabetogenic posttransplant setting [<a href="#rid88">88</a>].</p><p></p><p>Prediabetes includes impaired fasting glucose and/or impaired glucose tolerance and is diagnosed by a fasting plasma glucose between 100 and 125 mg/dL (5.6 and 6.9 mmol/L) or a two-hour plasma glucose between 140 and 199 mg/dL (7.8 and 11.0 mmol/L) during an OGTT, respectively, according to American Diabetes Association (ADA) guidelines. An A1C of 5.7 to 6.4 percent is also consistent with a prediabetic state [<a href="#rid89">89,90</a>]. Of note, the normal range of fasting plasma glucose differs according to ADA and WHO criteria; an abnormal fasting glucose is defined as ≥100 mg/dL (5.6 mmol/L) by the ADA and ≥110 mg/dL (6.1 mmol/L) by the WHO (see  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Diagnostic criteria'</a>). Among transplant recipients, the lower threshold advocated by the ADA is more sensitive in identifying patients at risk for PTDM [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3150466690"><span class="h1">MANAGEMENT OF HYPERGLYCEMIA IN THE FIRST 6 WEEKS AFTER TRANSPLANTATION</span></p><p class="headingAnchor" id="H459381612"><span class="h2">Immediate (&lt;1 week) posttransplantation</span><span class="headingEndMark"> — </span>Hyperglycemia is very common in the immediate posttransplant period. Since perioperative hyperglycemia is an important risk factor for the development of posttransplantation diabetes mellitus (PTDM), close monitoring and treatment of hyperglycemia are important aspects of inpatient management in the immediate posttransplant setting.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Critically ill patients</strong> – In the immediate postoperative period, blood glucose levels should be routinely monitored, and patients with hyperglycemia (blood glucose ≥180 mg/dL [10.0 mmol/L]) should be treated with insulin therapy using a standard intravenous (IV) insulin infusion protocol. This approach is consistent with the guidelines for inpatient glycemic control from the American Diabetes Association (ADA) [<a href="#rid91">91-93</a>]. Optimal glycemic targets for the immediate posttransplant period have not been clearly defined. We, and many transplant centers, target blood glucose readings between 140 to 180 mg/dL (7.8 to 10.0 mmol/L) in patients who are critically ill and receiving an insulin infusion [<a href="#rid94">94,95</a>]. (See  <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients", section on 'Insulin infusion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noncritically ill patients</strong> – When patients are stable and no longer critically ill, we transition from insulin infusion to a subcutaneous insulin regimen. In patients without a previous history of diabetes who require less than 2 units of IV insulin for several (six to eight) hours prior to the transition, the use of correction insulin sliding scale before meals and bedtime (or every six hours if not eating) is generally adequate [<a href="#rid96">96</a>]. Given the heterogeneity of the disease, however, the transition from IV to subcutaneous insulin may need to be individualized, and variables such as glucocorticoid dose and profile, allograft function, concurrent infection, and nutritional source (eg, not eating, enteral or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>) should be considered. Among noncritically ill patients, we target a fasting (premeal) blood glucose of &lt;140 mg/dL (7.8 mmol/L) and random blood glucose of &lt;180 mg/dL (10.0 mmol/L) [<a href="#rid91">91-93,97</a>].</p><p></p><p>There are no studies that have specifically compared early insulin therapy with noninsulin agents in the immediate posttransplant setting. However, data from one randomized trial of 50 kidney transplant recipients showed that early basal insulin therapy, compared with short-acting insulin and/or oral hypoglycemic agents, reduced the risk of developing PTDM within the first year after transplant by 73 percent [<a href="#rid98">98</a>]. The authors of this study postulated that early exogenous insulin therapy might protect beta cells from the toxic effects of immunosuppressive therapy and inflammatory stress.</p><p>More intensive blood glucose control has not been shown to be beneficial among patients undergoing solid organ transplantation [<a href="#rid94">94,95</a>]. As an example, in one small randomized trial of 104 patients undergoing kidney transplantation that compared intensive (blood glucose target 70 to 110 mg/dL) versus standard (blood glucose target &lt;180 mg/dL) glycemic control, patients in the intensive glycemic control group experienced higher rates of graft rejection, delayed graft function, and hypoglycemia [<a href="#rid94">94</a>].</p><p>More details regarding the management of hyperglycemia and diabetes in hospitalized patients are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients", section on 'Our approach'</a>.)</p><p></p><p>The intraoperative management of hyperglycemia during kidney transplantation is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/102390.html" rel="external">"Anesthesia for kidney transplantation", section on 'Management of hyperglycemia'</a>.)</p><p class="headingAnchor" id="H242147455"><span class="h2">Early (1 to 6 weeks) posttransplantation</span><span class="headingEndMark"> — </span>Upon discharge from the hospital, transplant recipients with persistent hyperglycemia, particularly those requiring insulin therapy, should be instructed to perform self-monitoring of blood glucose (SMBG) at home. The optimal frequency of SMBG is not known for this patient population. We suggest initially checking a blood glucose once or twice per day, usually before breakfast (fasting) and again in the afternoon or evening before dinner [<a href="#rid86">86</a>]. Further testing is determined based upon the severity of hyperglycemia and treatment approach. If blood glucose readings are consistently in the normal range, patients can be advised to discontinue SMBG.</p><p>There is no high-quality evidence to guide the optimal treatment of hyperglycemia in the early posttransplant period. In addition, the optimal glycemic target in this specific population is not known. We use glycemic targets that are similar to those established by the ADA for nontransplant patients with diabetes (see  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Blood glucose monitoring and target A1C'</a>). Our approach to treatment, which is largely consistent with the recommendations of the 2014 international consensus meeting on PTDM [<a href="#rid1">1</a>], is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In most hospitalized patients with hyperglycemia requiring insulin (ie, total daily dose of ≥20 units of insulin) in the immediate posttransplant period (see <a class="local">'Immediate (&lt;1 week) posttransplantation'</a> above), we continue insulin therapy after hospital discharge. Insulin provides the advantage of easy titration during the first few days after discharge, avoiding the need for urgent visits for hyperglycemic episodes. Many transplant centers have access to diabetes educators or nurse champions with specialized diabetes education training who can train patients on the use of insulin therapy, glucose monitoring, and survival skills.</p><p></p><p class="bulletIndent1">We typically prefer intermediate-acting neutral protamine hagedorn (NPH) insulin, administered as a single daily dose (initially 5 to 10 units and adjusted based upon the afternoon glucose levels) at the same time as the glucocorticoid dose in the morning [<a href="#rid99">99,100</a>]. The timing of this dose matches the typical afternoon glucose peak that is observed with glucocorticoid-induced hyperglycemia in nondiabetic and diabetic individuals [<a href="#rid101">101</a>]. Alternative options include <a class="drug drug_general" data-topicid="9023" href="/z/d/drug information/9023.html" rel="external">insulin glargine</a>, administered at night and dose adjusted to control the morning fasting glucose level, or premeal short-acting <a class="drug drug_general" data-topicid="9020" href="/z/d/drug information/9020.html" rel="external">insulin aspart</a> or <a class="drug drug_general" data-topicid="9025" href="/z/d/drug information/9025.html" rel="external">insulin lispro</a>, based upon premeal glucose levels and anticipated carbohydrate ingestion. Insulin pump therapy is rarely necessary or indicated in this setting.</p><p></p><p class="bulletIndent1">The duration of insulin treatment depends upon the patient's response to therapy as well as subsequent blood glucose monitoring. Patients whose insulin requirements decrease to &lt;20 units per day can be transitioned to oral hypoglycemic agents, as discussed below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with mild hyperglycemia and low insulin requirements (ie, total daily dose of &lt;20 units of insulin) in the immediate posttransplant period, we treat with oral hypoglycemic agents rather than insulin. We prefer to use agents that have a lower risk of hypoglycemia and have low or no renal excretion, such as meglitinides (eg, <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a>) or dipeptidyl peptidase 4 (DPP-4) inhibitors (eg, <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a>, <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a>, <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">saxagliptin</a>, <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">alogliptin</a>, vildagliptin). If a meglitinide or DPP-4 inhibitor cannot be used, a sulfonylurea such as <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a>, which has a lower risk of hypoglycemia in patients with kidney impairment, is another option. This is particularly relevant during the early posttransplant period, when patients are experiencing dynamic changes in kidney function and dose adjustments in their immunosuppression regimen. The use of oral hypoglycemic agents to treat posttransplant hyperglycemia is similar to that for patients with established PTDM and is discussed elsewhere in this topic. (See <a class="local">'Oral hypoglycemic agents'</a> below.)</p><p></p><p class="headingAnchor" id="H2636892691"><span class="h1">MANAGEMENT OF PTDM</span><span class="headingEndMark"> — </span>Most kidney transplant recipients with posttransplant hyperglycemia will experience an improvement of their hyperglycemia once the doses of immunosuppressive agents and glucocorticoids are reduced after transplantation [<a href="#rid24">24</a>]. However, some patients will develop chronic hyperglycemia and may be diagnosed with posttransplantation diabetes mellitus (PTDM) in the late posttransplant setting. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p>In patients with PTDM or posttransplant prediabetes (ie, impaired fasting glucose or impaired glucose tolerance), we and most experts take a stepwise approach to the management of chronic hyperglycemia [<a href="#rid1">1</a>]. This starts with lifestyle modification, which includes dietary modification, weight reduction, and exercise, and is followed by pharmacologic therapy, first with oral hypoglycemic agents and then with insulin therapy. In kidney transplant recipients with PTDM, the goals of outpatient therapy are to improve glycemic control to lower the risk of microvascular complications and to reduce the risk of cardiovascular disease. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H2936074701"><span class="h2">Lifestyle modification</span><span class="headingEndMark"> — </span>In all kidney transplant recipients with PTDM, we suggest lifestyle modification interventions focusing on dietary modification, weight reduction, and physical exercise. Lifestyle modification should be attempted prior to the initiation of pharmacologic therapy for PTDM.</p><p>Studies examining the effects of lifestyle interventions in the transplant population are limited [<a href="#rid102">102,103</a>]. One trial that randomly assigned 130 nondiabetic kidney transplant recipients to receive active (lifestyle advice delivered by kidney dietitians using behavior change techniques) or passive (lifestyle modification leaflets alone) lifestyle intervention found no significant difference between the groups in insulin secretion, insulin sensitivity, or disposition index after six months of follow-up [<a href="#rid102">102</a>]. However, lifestyle modification may be beneficial based upon data in nontransplant patients with type 2 diabetes mellitus. These issues are discussed in more detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Medical nutrition therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Weight management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Exercise'</a>.)</p><p></p><p class="headingAnchor" id="H791947624"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Pharmacologic therapy for PTDM should begin with oral hypoglycemic agents. If adequate glycemic control cannot be achieved with oral agents, patients can be started on insulin therapy.</p><p class="headingAnchor" id="H2275508375"><span class="h3">Oral hypoglycemic agents</span><span class="headingEndMark"> — </span>There is insufficient evidence to support a first-line agent for the chronic management of hyperglycemia in PTDM [<a href="#rid2">2,104,105</a>]. Drug selection should consider efficacy, side effects, potential drug-drug interactions, and cost.</p><p>In general, we start oral treatment with sulfonylureas, meglitinides, or DPP-4 inhibitors, although data demonstrating their safety and efficacy in kidney transplant recipients with PTDM are limited. We tend not to use <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, given the potential (but rare) risk for lactic acidosis in the setting of kidney function impairment. We do not routinely use glucagon-like peptide (GLP) 1 agonists, alpha-glucosidase inhibitors, or sodium-glucose co-transporter 2 (SGLT2) inhibitors as first-line oral agents; however, these agents may be considered in patients who require additional therapy or who do not tolerate initial oral therapy. Emerging data suggest that SGLT2 inhibitors may be associated with benefits beyond glycemic control in kidney transplant recipients. Thiazolidinediones are generally not used among transplant recipients.</p><p>The following discussion of oral therapy emphasizes those aspects specific to kidney transplant recipients. General discussions of the use of these agents are presented in separate topic reviews.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sulfonylureas</strong> – Among the sulfonylureas, <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">glipizide</a> and <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> are preferred to <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> when the estimated glomerular filtration rate (eGFR) is less than 50 mL/min/1.73 m<sup>2</sup> because glyburide may accumulate with kidney function impairment, resulting in hypoglycemia. We usually begin with glipizide at 2.5 to 5 mg orally daily and then advance to 10 mg twice per day as necessary to maintain the glycated hemoglobin (A1C) level at less than 7 percent. Less than 5 percent of glipizide is renally excreted and does not change levels of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in kidney transplant recipients [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Sulfonylureas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meglitinides</strong> – Meglitinides, such as <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">repaglinide</a>, have been shown to be effective in some PTDM patients. One six-month study found that repaglinide lowered mean A1C levels (7.6 to 5.8 percent) in 14 of 23 patients with PTDM, with the remainder eventually requiring insulin therapy [<a href="#rid106">106</a>]. However, a higher cost than sulfonylureas and two- or three-times daily dosing may be a limitation. (See  <a class="medical medical_review" href="/z/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Meglitinides'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dipeptidyl peptidase 4 (DPP-4) inhibitors</strong> – DPP-4 inhibitors (<a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a>, <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a>, <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">saxagliptin</a>, <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">alogliptin</a>, vildagliptin) cause a glucose-dependent increase in insulin release. Limited data suggest that DPP-4 inhibitors are generally safe and effective in kidney transplant recipients. (See  <a class="medical medical_review" href="/z/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">With the exception of <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a>, which is primarily eliminated via the enterohepatic system, all DPP-4 inhibitors are mainly cleared by the kidneys and require dose reduction in patients with moderate to severe kidney impairment. In general, DPP-4 inhibitors do not have any significant drug interactions with maintenance immunosuppressive agents, with the possible exception of <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a>, which may cause an increase in <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> trough levels [<a href="#rid107">107,108</a>]. The use of these agents may be limited by their high cost.</p><p></p><p class="bulletIndent1">Only <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a>, <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a>, and vildagliptin have been evaluated in kidney transplant recipients [<a href="#rid107">107,109-112</a>]. Three reports have documented the safety and efficacy of sitagliptin for treatment of PTDM in kidney transplant recipients; both first- and second-phase insulin secretion responses increased significantly in sitagliptin-treated patients [<a href="#rid109">109,110,112</a>]. Although sitagliptin does not cause hypoglycemia, it may prolong the QT interval, especially if used with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. A randomized controlled trial of vildagliptin versus placebo in 33 stable kidney transplant recipients with PTDM identified by oral glucose tolerance test (OGTT) demonstrated significant improvement in OGTT-derived two-hour plasma glucose (183 versus 231 mg/dL) and A1C (6.1 versus 6.5 percent) after three months of treatment with similar and mild adverse events between groups [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1">Whether any specific DPP-4 inhibitor is more effective or easier to use in kidney transplant recipients is unclear. In a retrospective study from Korea that compared the glucose-lowering efficacies of different DPP-4 inhibitors in kidney transplant patients with diabetes, a greater decrease in A1C was observed in patients treated with <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">linagliptin</a> compared with those treated with vildagliptin or <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a> (-1.40 versus -0.38 and -0.53 percent, respectively) [<a href="#rid107">107</a>]. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> trough levels were significantly increased among patients treated with sitagliptin compared with those treated with vildagliptin but were minimally changed in those treated with linagliptin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> – We generally do not use metformin, because kidney function impairment increases the risk of lactic acidosis with this agent. However, this is considered to be a rare event [<a href="#rid113">113</a>], and the 2016 changes in labeling of metformin allow initiation of metformin in patients with an eGFR as low as 45 mL/min/1.73 m<sup>2</sup>. In the United States, it is strictly contraindicated in patients with an eGFR of &lt;30 mL/min/1.73 m<sup>2</sup> and not recommended if the eGFR is between 30 and 45 mL/min/1.73 m<sup>2</sup>. Some experts advocate for metformin based upon data from observational studies and one small randomized trial of patients with impaired glucose tolerance that have shown favorable patient and graft outcomes as well as safety and efficacy [<a href="#rid114">114-116</a>]. (See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucagon-like peptide (GLP) 1 receptor agonists</strong> – GLP-1 receptor agonists (<a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a>, <a class="drug drug_general" data-topicid="9005" href="/z/d/drug information/9005.html" rel="external">exenatide</a>, <a class="drug drug_general" data-topicid="97148" href="/z/d/drug information/97148.html" rel="external">dulaglutide</a>, <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">semaglutide</a>, <a class="drug drug_general" data-topicid="109304" href="/z/d/drug information/109304.html" rel="external">lixisenatide</a>) improve glycemic control by enhancing glucose-dependent insulin secretion, delaying gastric emptying, regulating postprandial glucagon, and reducing food intake. We do not routinely use GLP-1 receptor agonists as initial oral pharmacologic therapy in kidney transplant recipients with PTDM given the limited evidence for their use in this patient population. In one retrospective study of 17 kidney transplant recipients (11 with PTDM, 3 with pretransplant diabetes), treatment with a GLP-1 receptor agonist (mostly liraglutide) was associated with a reduction in the total daily insulin dose and risk of hypoglycemia in patients who were on therapy for at least 12 months [<a href="#rid117">117</a>]. Kidney allograft function remained stable, and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> dosing did not require adjustment. Five patients (29 percent) discontinued therapy, four due to adverse effects and one due to uncontrolled hyperglycemia. (See  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-glucosidase inhibitors</strong> – Alpha-glucosidase inhibitors such as <a class="drug drug_general" data-topicid="9219" href="/z/d/drug information/9219.html" rel="external">acarbose</a> or <a class="drug drug_general" data-topicid="9538" href="/z/d/drug information/9538.html" rel="external">miglitol</a> are not considered first- or second-line agents but may be considered if other options are not available. Alpha-glucosidase inhibitors slow carbohydrate absorption and reduce postprandial blood-sugar peaks. They are relatively less effective in lowering glycemia, compared with other antidiabetic medications, but do not cause weight gain. These agents are relatively inexpensive, but their use may be limited by common gastrointestinal side effects, particularly in the setting of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) treatment. There is a reduced risk of hypoglycemia [<a href="#rid118">118</a>]. (See  <a class="medical medical_review" href="/z/d/html/1787.html" rel="external">"Alpha-glucosidase inhibitors for treatment of diabetes mellitus", section on 'General approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiazolidinediones</strong> – Thiazolidinediones are generally not used among transplant recipients, unless there are no other alternatives. We do not use <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> in any transplant recipient. The thiazolidinediones may worsen immunosuppression-associated bone loss and are commonly associated with formation of edema, which may necessitate the use of diuretics and may predispose to calcineurin toxicity. Use of these agents is also contraindicated in hepatic dysfunction. (See  <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sodium-glucose co-transporter 2 (SGLT2) inhibitors</strong> – SGLT2 inhibitors (<a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a>) inhibit glucose absorption in the proximal tubule, causing glucosuria, weight loss, and improved glycemic control [<a href="#rid119">119</a>]. In nontransplant patients with chronic kidney disease (CKD), the use of SGLT2 inhibitors has been shown to lower the risk of kidney failure and cardiovascular events [<a href="#rid120">120</a>]. (See  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">We do not recommend the routine use of SGLT2 inhibitors in kidney transplant recipients with PTDM at this time, given the limited efficacy and safety data in this patient population. However, some clinicians may treat PTDM with SGLT2 inhibitors on a case by case basis. Because these agents cause glucosuria, there is an increased incidence of urinary tract infections, which already have an increased incidence in kidney transplant recipients. These drugs appear to have minimal drug-drug interactions with common immunosuppressants, with the possible exception of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1">Data examining the safety and efficacy of SGLT2 inhibitors in kidney transplant recipients with PTDM are limited but increasing [<a href="#rid121">121-125</a>]. In one small trial that randomly assigned 44 kidney transplant recipients with PTDM to <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a> (10 mg daily) or placebo for 24 weeks, treatment with empagliflozin produced a greater decrease in A1C compared with placebo (-0.2 versus 0.1 percent, respectively) [<a href="#rid121">121</a>]. However, the magnitude of this reduction was limited and dependent upon eGFR and baseline A1C. At 24 weeks, there were no differences between the groups in adverse events, immunosuppressive drug levels, or eGFR. Another small case series of 10 patients treated with <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">canagliflozin</a> reported modest reductions in A1C over a mean of 10 months of follow-up, without any urinary or mycotic infections [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1">Observational studies suggest that the use of SGLT2 inhibitors in kidney transplant recipients with PTDM may be associated with benefits beyond glycemic control [<a href="#rid125">125-127</a>]. As an example, in one study that compared outcomes among 2083 kidney transplant recipients with diabetes (475 with PTDM, 1608 with pretransplant diabetes) who were or were not receiving an SGLT2 inhibitor, use of an SGLT2 inhibitor was associated with lower risks of death-censored graft failure (adjusted hazard ratio [HR] 0.31, 95% CI 0.09-0.98) and doubling of serum creatinine (adjusted HR 0.45, 95% CI 0.23-0.88) [<a href="#rid125">125</a>]. Approximately 16 percent of recipients receiving an SGLT2 inhibitor experienced an acute decrease in eGFR of &gt;10 percent during the first month of use, but the eGFR recovered thereafter. The initial decrease in eGFR should not warrant discontinuation or preclude use of an SGLT2 inhibitor [<a href="#rid126">126</a>].</p><p></p><p class="headingAnchor" id="H1104387659"><span class="h3">Insulin therapy</span><span class="headingEndMark"> — </span>Many patients will require initiation of insulin, especially those with blood sugars above 200 mg/dL (11.1 mmol/L). We initiate insulin therapy if oral agents have not been effective or have been accompanied by unacceptable side effects, or if A1C levels are consistently above 7 percent.</p><p>Diurnal glucose patterns differ among patients who are receiving glucocorticoids, compared with those who are not. Thus, even with small doses of glucocorticoids of 5 mg per day in the morning, we have typically observed a late-afternoon or early-evening peak in blood glucose concentration that is often much higher than the fasting blood-glucose concentrations.</p><p>There are little data regarding insulin therapy among patients who are receiving glucocorticoids.</p><p>A detailed discussion of insulin therapy is available in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1796.html" rel="external">"Management of blood glucose in adults with type 1 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H2634516233"><span class="h2">Adjustment of immunosuppression</span><span class="headingEndMark"> — </span>Adjustment of immunosuppression therapy aimed at improving glucose tolerance may be considered among patients with PTDM. However, the potential benefit of altering immunosuppressive agents must be weighed against the risk of allograft rejection and is not recommended as standard-of-care management.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – The glucocorticoid dose should be decreased as soon as possible, but complete glucocorticoid withdrawal is not recommended [<a href="#rid6">6</a>]. <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">Prednisolone</a> dose reduction to 5 mg/day at one year has been associated with a decrease in glucose intolerance from 55 to 34 percent [<a href="#rid27">27</a>]. Although complete glucocorticoid withdrawal can reduce the incidence of PTDM, a significant percentage of patients suffer a rejection episode requiring reinstitution of glucocorticoid therapy [<a href="#rid128">128</a>]. One study also found no improvement in insulin sensitivity when dropping from 5 mg to complete prednisolone withdrawal [<a href="#rid30">30</a>]. Though not well studied in transplant recipients, divided dosing may reduce variability and peak of glucocorticoid-induced hyperglycemia [<a href="#rid129">129</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> – Compared with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, the use of tacrolimus is associated with higher rates of PTDM, particularly with tacrolimus trough levels &gt;15 ng/mL in the first month posttransplant (see <a class="local">'Modifiable risk factors'</a> above). Thus, in affected patients, consideration should be given to reducing the tacrolimus dose.</p><p></p><p>We generally do not switch patients with PTDM from <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> to <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, unless there are other tacrolimus-related side effects, since the effect of tacrolimus on glucose tolerance may be reversible even if the agent is not discontinued. In one study, for example, 70 percent of White patients and 20 percent of African American patients were able to discontinue insulin without discontinuing tacrolimus or glucocorticoids [<a href="#rid130">130</a>]. In addition, one large review reported an improved graft survival with tacrolimus therapy despite the increased rate of PTDM seen with tacrolimus and the association of PTDM with decreased graft survival [<a href="#rid13">13</a>]. Another registry analysis of the United States Renal Data System (USRDS) database of nearly 50,000 patients transplanted between January 1998 and December 2002 (during which time tacrolimus and cyclosporine had equal market share) showed that diabetes was associated with worse patient and graft survival but no differences based on whether tacrolimus or cyclosporine was used despite a higher incidence of PTDM among those who received tacrolimus [<a href="#rid131">131</a>].</p><p>However, some studies suggest that switching from <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> to <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may improve glucose control and return normal glucose tolerance. A small trial randomly assigned 67 kidney transplant recipients with PTDM to cyclosporine conversion versus tacrolimus continuation and demonstrated a significant improvement in A1C in the cyclosporine arm and reversal of PTDM [<a href="#rid132">132</a>]. Another randomized trial showed the benefit of switching tacrolimus to cyclosporine in recipients who developed PTDM, with 34 percent of subjects in the cyclosporine conversion group versus 10 percent in the tacrolimus continuation group resolving their PTDM [<a href="#rid133">133</a>]. Thus, switching to cyclosporine may be considered among patients in whom diabetes remains difficult to control on lower-dose tacrolimus [<a href="#rid6">6</a>].</p><p>Conversion to mTOR inhibitors (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) is not recommended to reduce the risk of or reverse PTDM. Sirolimus may worsen insulin resistance and glycemia [<a href="#rid48">48,134</a>].</p><p>Conversion to <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> is not generally performed for the indication of PTDM alone. However, patients who are converted from <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> to belatacept for other indications may experience an improvement in glucose control [<a href="#rid135">135</a>].</p><p class="headingAnchor" id="H3318125484"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>In kidney transplant recipients with PTDM, an A1C should be checked every three months. The optimal glycemic target for kidney transplant recipients with PTDM is not known. In general, the goals for glycemic control in kidney transplant recipients are similar to those in nontransplant patients with diabetes and should take into account such factors as duration of diabetes, comorbid conditions, the risk for hypoglycemia, and life expectancy. A reasonable goal for most patients, as recommended by the ADA, is an A1C of ≤7 percent. This goal should be set somewhat higher (eg, &lt;8 percent) for older patients and those with a limited life expectancy. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend an A1C goal of 7 to 7.5 percent for kidney transplant recipients [<a href="#rid136">136</a>]. (See  <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'</a>.)</p><p>The A1C assay will not reliably measure average glucose levels in the setting of anemia, especially if erythropoietin replacement is being used. Patients should be instructed in glucose self-monitoring. Patients should have regular screening for retinopathy and neuropathy. Regular foot care is also indicated.</p><p class="headingAnchor" id="H1399710170"><span class="h1">PROGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient survival</strong> – The development of posttransplantation diabetes mellitus (PTDM) has an adverse effect upon patient survival in most studies [<a href="#rid13">13,32,53,54,137-146</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, one-year patient survival was 83 and 98 percent in those with and without PTDM, respectively [<a href="#rid53">53</a>]. A subsequent report found that five-year survival with PTDM was 87 versus 93 percent among nondiabetic patients [<a href="#rid76">76</a>]. However, these studies were performed in the era of high-dose glucocorticoid use and cyclosporine-based regimens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, a subsequent analysis of 628 kidney transplant recipients followed for a median of 56 months after transplant found no association between new-onset PTDM and death with a functioning graft [<a href="#rid147">147</a>]. Tighter glucose monitoring, more intensive glycemic control, and glucocorticoid minimization may have explained the reduced impact of PTDM on patient survival in this study.</p><p></p><p class="bulletIndent1">The development of PTDM correlates with increased cardiovascular mortality, which is the most prevalent cause of poor long-term survival [<a href="#rid13">13,148-153</a>]. The increased relative risk (RR) for death from cardiovascular disease ranges from 1.5 to 3 among those who develop PTDM versus those without diabetes [<a href="#rid13">13,149,151</a>]. Some of the excess risk is associated with coexistence of other cardiovascular risk factors, particularly increased age and dyslipidemia [<a href="#rid151">151</a>].</p><p></p><p class="bulletIndent1">The effect of new-onset PTDM on cardiovascular or overall mortality may not be as great as the adverse effects of pretransplant diabetes on mortality, at least at 1.5 years. This was suggested by a large cohort study that examined outcomes of 37,448 recipients who had survived for longer than one year with a functioning transplant [<a href="#rid154">154</a>]. Recipients were stratified according to the absence or presence of diabetes and occurrence of acute rejection at one year following transplant. At a median follow-up of 1.5 years, pretransplant diabetes, but not new-onset diabetes, was associated with higher all-cause and cardiovascular mortality. This study is limited by the short duration of follow-up; 1.5 years may not be sufficient to show an adverse effect of new-onset diabetes [<a href="#rid155">155</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allograft survival</strong> – Most, but not all, studies have shown that PTDM decreases long-term allograft survival. In one study, for example, graft survival at 12 years was 48 and 70 percent in those with and without PTDM, respectively [<a href="#rid156">156</a>]; this was associated with a RR of loss of 3.72.</p><p></p><p class="bulletIndent1">Most, if not all, of the adverse effect on allograft survival is due to the increase in mortality associated with PTDM. As an example, in a retrospective analysis of 27,707 transplant recipients, PTDM was associated with increased risk for allograft failure from any cause but not for death-censored graft loss (or graft loss without death) [<a href="#rid142">142</a>]. However, another large, retrospective study suggested that PTDM was associated with increased risk for both overall allograft failure and for death-censored allograft failure [<a href="#rid13">13</a>]. Unlike the study cited above, however [<a href="#rid142">142</a>], this study did not control for acute rejection in the multivariate analysis.</p><p></p><p class="bulletIndent1">The mechanism by which PTDM may decrease allograft survival independent of increased mortality is not clear. Some have suggested that the occurrence of diabetic nephropathy may contribute to the increased rate of graft failure without death [<a href="#rid157">157</a>]. Another possibility is that efforts to decrease diabetogenic immunosuppressive therapy in order to prevent PTDM and its complications may increase rates of rejection [<a href="#rid156">156</a>].</p><p></p><p class="bulletIndent1">However, the effect of diabetes on death-censored allograft loss is less than that of acute rejection. This was demonstrated in the study cited above that showed that acute rejection, but not diabetes, was associated with higher death-censored transplant failure at a median follow-up of 1.5 years [<a href="#rid154">154</a>]. Although limited by the short follow-up time, this large study suggests that acute rejection is the most significant potentially modifiable factor in allograft survival and underlines the importance of maintaining adequate immunosuppression to prevent rejection, even at the expense of the development of new-onset diabetes [<a href="#rid155">155</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – PTDM has been associated with an increased risk for infection and sepsis, with hyperglycemia possibly altering the immune response [<a href="#rid53">53,76,141,156,158</a>]. Urinary tract infection, pneumonia, and cytomegalovirus (CMV) have also been reported to occur at increased rates with diabetes [<a href="#rid53">53,76,141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetic complications</strong> – Metabolic and microvascular complications observed in nontransplant patients with diabetes are also observed in those who develop PTDM. This was shown in a retrospective study of 4105 patients who developed PTDM by three years posttransplantation [<a href="#rid159">159</a>]. Ophthalmic and neurologic complications occurred in 8 and 16 percent of patients, respectively [<a href="#rid159">159</a>]. These complications developed at an accelerated rate compared with those in nontransplant patients.</p><p></p><p class="bulletIndent1">Diabetic complications may occur at a faster rate in those treated with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> compared with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid159">159</a>]. (See <a class="local">'Modifiable risk factors'</a> above.)</p><p></p><p class="headingAnchor" id="H2602832523"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H224958183"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Diabetes occurs in a moderate fraction (approximately 20 percent) of patients following kidney transplantation. Posttransplantation diabetes mellitus (PTDM) is associated with increased mortality and morbidity and, in particular, higher rates of kidney transplant rejection, cardiovascular disease, and infection, which are the leading causes of death in kidney transplant recipients. (See <a class="local">'Introduction'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– Several modifiable and nonmodifiable factors may increase the risk for PTDM among kidney transplant recipients, including immunosuppressive agents, preoperative impaired glucose tolerance and perioperative hyperglycemia, obesity, infection, and hypomagnesemia. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis </strong>– All kidney transplant recipients, whether or not they have a pre-identified increased risk, should be routinely evaluated for and informed about the risk of PTDM after transplantation. The diagnosis of PTDM should ideally be made when patients are stable on their maintenance immunosuppression regimen, with stable kidney allograft function and in the absence of acute infection. Transient posttransplant hyperglycemia is very common in the immediate-to-early posttransplant period but usually resolves within the first few weeks after transplantation. Thus, to avoid labeling the majority of kidney transplant recipients with PTDM in the immediate-to-early posttransplant period, a formal diagnosis of PTDM should <strong>not </strong>be made in patients within the first six weeks after transplantation. PTDM may be diagnosed after transplantation based upon diagnostic criteria similar to those used in the nontransplant population. (See <a class="local">'Evaluation and diagnosis of PTDM'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hyperglycemia in the early posttransplant period </strong>– Our approach to the management of hyperglycemia <strong>in the first six weeks</strong> after transplantation is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immediate (&lt;1 week) posttransplantation</strong> – In the immediate postoperative period, blood glucose levels should be routinely monitored, and patients with hyperglycemia (plasma glucose ≥180 mg/dL [10.0 mmol/L]) should be treated with insulin therapy using a standard intravenous (IV) insulin infusion protocol. When patients are stable and no longer critically ill, we transition from insulin infusion to a subcutaneous insulin regimen. (See <a class="local">'Immediate (&lt;1 week) posttransplantation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early (1 to 6 weeks) posttransplantation</strong> – Upon discharge from the hospital, transplant recipients with persistent hyperglycemia, particularly those requiring insulin therapy, should be instructed to perform self-monitoring of blood glucose (SMBG) at home. In most hospitalized patients with hyperglycemia requiring insulin (ie, total daily dose of ≥20 units of insulin) in the immediate posttransplant period, we continue insulin therapy after hospital discharge. In patients with mild hyperglycemia and low insulin requirements (ie, total daily dose of &lt;20 units of insulin) in the immediate posttransplant period, we treat with oral hypoglycemic agents rather than insulin. (See <a class="local">'Early (1 to 6 weeks) posttransplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of PTDM </strong>– In patients with established PTDM or with prediabetes (impaired fasting glucose or impaired glucose tolerance), we and most experts take a stepwise approach to the management of chronic hyperglycemia. This starts with lifestyle modification, which includes dietary modification, weight reduction, and exercise, and is followed by pharmacologic therapy, first with oral hypoglycemic agents and then with insulin therapy. Adjustment of immunosuppression therapy aimed at improving glucose tolerance may be considered among patients with PTDM. However, the potential benefit of altering immunosuppressive agents must be weighed against the risk of allograft rejection. (See <a class="local">'Management of PTDM'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014; 14:1992.</a></li><li><a class="nounderline abstract_t">Galindo RJ, Fried M, Breen T, Tamler R. HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES. Endocr Pract 2016; 22:454.</a></li><li><a class="nounderline abstract_t">Werzowa J, Hecking M, Haidinger M, et al. The diagnosis of posttransplantation diabetes mellitus: meeting the challenges. Curr Diab Rep 2015; 15:27.</a></li><li><a class="nounderline abstract_t">Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. Diabetes Care 2013; 36:2763.</a></li><li><a class="nounderline abstract_t">Gupta S, Pollack T, Fulkerson C, et al. Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus. J Endocr Soc 2018; 2:1314.</a></li><li><a class="nounderline abstract_t">Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75:SS3.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42:S13.</a></li><li class="breakAll">http://www.who.int/diabetes/publications/report-hba1c_2011.pdf (Accessed on October 14, 2019).</li><li><a class="nounderline abstract_t">Galindo RJ, Fayfman M, Umpierrez GE. Perioperative Management of Hyperglycemia and Diabetes in Cardiac Surgery Patients. Endocrinol Metab Clin North Am 2018; 47:203.</a></li><li class="breakAll">Starlz, TE. Experience in Renal Transplantation, W.B. Saunders Company, Philadelphia 1964.</li><li><a class="nounderline abstract_t">Gunnarsson R, Arner P, Lundgren G, et al. Diabetes mellitus--a more-common-than-believed complication of renal transplantation. Transplant Proc 1979; 11:1280.</a></li><li><a class="nounderline abstract_t">Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4:583.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178.</a></li><li><a class="nounderline abstract_t">Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59:732.</a></li><li><a class="nounderline abstract_t">Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88:429.</a></li><li><a class="nounderline abstract_t">David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007; 84:50.</a></li><li><a class="nounderline abstract_t">Sulanc E, Lane JT, Puumala SE, et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 2005; 80:945.</a></li><li><a class="nounderline abstract_t">Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7:1506.</a></li><li><a class="nounderline abstract_t">Porrini E, Moreno JM, Osuna A, et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. Transplantation 2008; 85:1133.</a></li><li><a class="nounderline abstract_t">Mourad G, Glyda M, Albano L, et al. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. Transplantation 2017; 101:1924.</a></li><li><a class="nounderline abstract_t">Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant 2015; 15 Suppl 2:1.</a></li><li><a class="nounderline abstract_t">Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2017 Annual Data Report: Kidney. Am J Transplant 2019; 19 Suppl 2:19.</a></li><li><a class="nounderline abstract_t">Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3:590.</a></li><li><a class="nounderline abstract_t">Porrini EL, Díaz JM, Moreso F, et al. Clinical evolution of post-transplant diabetes mellitus. Nephrol Dial Transplant 2016; 31:495.</a></li><li><a class="nounderline abstract_t">Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64:979.</a></li><li><a class="nounderline abstract_t">Boots JM, Christiaans MH, Van Duijnhoven EM, et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74:1703.</a></li><li><a class="nounderline abstract_t">Hjelmesaeth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001; 16:829.</a></li><li><a class="nounderline abstract_t">Thomusch O, Wiesener M, Opgenoorth M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet 2016; 388:3006.</a></li><li><a class="nounderline abstract_t">Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.</a></li><li><a class="nounderline abstract_t">Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004; 15:3233.</a></li><li><a class="nounderline abstract_t">Serrano OK, Kandaswamy R, Gillingham K, et al. Rapid Discontinuation of Prednisone in Kidney Transplant Recipients: 15-Year Outcomes From the University of Minnesota. Transplantation 2017; 101:2590.</a></li><li><a class="nounderline abstract_t">Vesco L, Busson M, Bedrossian J, et al. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996; 61:1475.</a></li><li><a class="nounderline abstract_t">Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol 2008; 3 Suppl 2:S38.</a></li><li><a class="nounderline abstract_t">Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006; 82:1673.</a></li><li><a class="nounderline abstract_t">Gourishankar S, Jhangri GS, Tonelli M, et al. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 2004; 4:1876.</a></li><li><a class="nounderline abstract_t">Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011; 91:334.</a></li><li><a class="nounderline abstract_t">Krämer BK, Zülke C, Kammerl MC, et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3:982.</a></li><li><a class="nounderline abstract_t">van Hooff JP, Christiaans MH, van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005; 79:1465.</a></li><li><a class="nounderline abstract_t">Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562.</a></li><li><a class="nounderline abstract_t">Burroughs TE, Lentine KL, Takemoto SK, et al. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol 2007; 2:517.</a></li><li><a class="nounderline abstract_t">Torres A, Hernández D, Moreso F, et al. Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus. Kidney Int Rep 2018; 3:1304.</a></li><li><a class="nounderline abstract_t">Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001; 72:1655.</a></li><li><a class="nounderline abstract_t">Rostaing L, Bunnapradist S, Grinyó JM, et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. Am J Kidney Dis 2016; 67:648.</a></li><li><a class="nounderline abstract_t">Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34:1.</a></li><li><a class="nounderline abstract_t">Dai C, Walker JT, Shostak A, et al. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable. JCI Insight 2020; 5.</a></li><li><a class="nounderline abstract_t">Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68:396.</a></li><li><a class="nounderline abstract_t">Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19:1411.</a></li><li><a class="nounderline abstract_t">Murakami N, Riella LV, Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 2014; 14:2317.</a></li><li><a class="nounderline abstract_t">Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 2011; 91:757.</a></li><li><a class="nounderline abstract_t">Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007; 30:609.</a></li><li><a class="nounderline abstract_t">Chakkera HA, Knowler WC, Devarapalli Y, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010; 5:1669.</a></li><li><a class="nounderline abstract_t">Wojtusciszyn A, Mourad G, Bringer J, Renard E. Continuous glucose monitoring after kidney transplantation in non-diabetic patients: early hyperglycaemia is frequent and may herald post-transplantation diabetes mellitus and graft failure. Diabetes Metab 2013; 39:404.</a></li><li><a class="nounderline abstract_t">Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44:376.</a></li><li><a class="nounderline abstract_t">Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62:1440.</a></li><li><a class="nounderline abstract_t">Araki M, Flechner SM, Ismail HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006; 81:335.</a></li><li><a class="nounderline abstract_t">Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13:1374.</a></li><li><a class="nounderline abstract_t">Abbott KC, Lentine KL, Bucci JR, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15:3166.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Martin P, Dixit V, et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5:2433.</a></li><li><a class="nounderline abstract_t">Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6:2232.</a></li><li><a class="nounderline abstract_t">Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004; 43:953.</a></li><li><a class="nounderline abstract_t">Gürsoy M, Köksal R, Karavelioğlu D, et al. Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients. Transplant Proc 2000; 32:580.</a></li><li><a class="nounderline abstract_t">Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001; 24:2121.</a></li><li><a class="nounderline abstract_t">Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47:1550.</a></li><li><a class="nounderline abstract_t">Mather HM, Nisbet JA, Burton GH, et al. Hypomagnesaemia in diabetes. Clin Chim Acta 1979; 95:235.</a></li><li><a class="nounderline abstract_t">Vanroelen WF, Van Gaal LF, Van Rooy PE, De Leeuw IH. Serum and erythrocyte magnesium levels in type I and type II diabetics. Acta Diabetol Lat 1985; 22:185.</a></li><li><a class="nounderline abstract_t">Nadler JL, Buchanan T, Natarajan R, et al. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993; 21:1024.</a></li><li><a class="nounderline abstract_t">Moles KW, McMullen JK. Insulin resistance and hypomagnesaemia: case report. Br Med J (Clin Res Ed) 1982; 285:262.</a></li><li><a class="nounderline abstract_t">Van Laecke S, Van Biesen W, Verbeke F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009; 9:2140.</a></li><li><a class="nounderline abstract_t">Huang JW, Famure O, Li Y, Kim SJ. Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation. J Am Soc Nephrol 2016; 27:1793.</a></li><li><a class="nounderline abstract_t">Augusto JF, Subra JF, Duveau A, et al. Relation between pretransplant magnesemia and the risk of new onset diabetes after transplantation within the first year of kidney transplantation. Transplantation 2014; 97:1155.</a></li><li><a class="nounderline abstract_t">Osorio JM, Bravo J, Pérez A, et al. Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes. Transplant Proc 2010; 42:2910.</a></li><li><a class="nounderline abstract_t">Garg N, Weinberg J, Ghai S, et al. Lower magnesium level associated with new-onset diabetes and pre-diabetes after kidney transplantation. J Nephrol 2014; 27:339.</a></li><li><a class="nounderline abstract_t">Santos L, Rodrigo E, Piñera C, et al. Elevated serum gamma-glutamyltransferase and hypomagnesemia are not related with new-onset diabetes after transplantation. Transplant Proc 2010; 42:2914.</a></li><li><a class="nounderline abstract_t">Mathew JT, Rao M, Job V, et al. Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant 2003; 18:164.</a></li><li><a class="nounderline abstract_t">Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003; 41:480.</a></li><li><a class="nounderline abstract_t">Sumrani N, Delaney V, Ding Z, et al. Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplant Proc 1991; 23:1249.</a></li><li><a class="nounderline abstract_t">Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83:36.</a></li><li><a class="nounderline abstract_t">Hjelmesaeth J, Hartmann A. Insulin resistance in patients with adult polycystic kidney disease. Nephrol Dial Transplant 1999; 14:2521.</a></li><li><a class="nounderline abstract_t">Ducloux D, Motte G, Vautrin P, et al. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant 1999; 14:1244.</a></li><li><a class="nounderline abstract_t">de Mattos AM, Olyaei AJ, Prather JC, et al. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005; 67:714.</a></li><li><a class="nounderline abstract_t">Cheungpasitporn W, Thongprayoon C, Vijayvargiya P, et al. The Risk for New-Onset Diabetes Mellitus after Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis. Can J Diabetes 2016; 40:521.</a></li><li><a class="nounderline abstract_t">Culliford A, Phagura N, Sharif A. Autosomal Dominant Polycystic Kidney Disease Is a Risk Factor for Posttransplantation Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. Transplant Direct 2020; 6:e553.</a></li><li><a class="nounderline abstract_t">Benson KA, Maxwell AP, McKnight AJ. A HuGE Review and Meta-Analyses of Genetic Associations in New Onset Diabetes after Kidney Transplantation. PLoS One 2016; 11:e0147323.</a></li><li><a class="nounderline abstract_t">Tarnowski M, Słuczanowska-Głabowska S, Pawlik A, et al. Genetic factors in pathogenesis of diabetes mellitus after kidney transplantation. Ther Clin Risk Manag 2017; 13:439.</a></li><li><a class="nounderline abstract_t">Kim YG, Ihm CG, Lee TW, et al. Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation. Transplantation 2012; 93:900.</a></li><li><a class="nounderline abstract_t">Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation 2013; 96:726.</a></li><li><a class="nounderline abstract_t">Shabir S, Jham S, Harper L, et al. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. Transpl Int 2013; 26:315.</a></li><li><a class="nounderline abstract_t">Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19:291.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1:S62.</a></li><li><a class="nounderline abstract_t">International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42:S173.</a></li><li><a class="nounderline abstract_t">Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009; 32:1119.</a></li><li><a class="nounderline abstract_t">Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 2012; 40:3251.</a></li><li><a class="nounderline abstract_t">Hermayer KL, Egidi MF, Finch NJ, et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab 2012; 97:4399.</a></li><li><a class="nounderline abstract_t">Wallia A, Schmidt K, Oakes DJ, et al. Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. J Clin Endocrinol Metab 2017; 102:451.</a></li><li><a class="nounderline abstract_t">Cardona S, Galindo RJ, Tsegka KG, et al. Simplified transition algorithm from intravenous to subcutaneous insulin in nondiabetic cardiac surgery patients with stress hyperglycemia. Diabetes 2018; 67 (Supplement 1).</a></li><li><a class="nounderline abstract_t">Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2022; 107:2101.</a></li><li><a class="nounderline abstract_t">Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23:739.</a></li><li><a class="nounderline abstract_t">Khowaja A, Alkhaddo JB, Rana Z, Fish L. Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial. Diabetes Ther 2018; 9:1647.</a></li><li><a class="nounderline abstract_t">Grommesh B, Lausch MJ, Vannelli AJ, et al. HOSPITAL INSULIN PROTOCOL AIMS FOR GLUCOSE CONTROL IN GLUCOCORTICOID-INDUCED HYPERGLYCEMIA. Endocr Pract 2016; 22:180.</a></li><li><a class="nounderline abstract_t">Burt MG, Roberts GW, Aguilar-Loza NR, et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96:1789.</a></li><li><a class="nounderline abstract_t">Kuningas K, Driscoll J, Mair R, et al. Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients: A Randomized Controlled Trial. Transplantation 2020; 104:1491.</a></li><li><a class="nounderline abstract_t">Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85:353.</a></li><li><a class="nounderline abstract_t">Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant 2011; 11:1376.</a></li><li><a class="nounderline abstract_t">Lo C, Jun M, Badve SV, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev 2017; 2:CD009966.</a></li><li><a class="nounderline abstract_t">Türk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6:842.</a></li><li><a class="nounderline abstract_t">Bae J, Lee MJ, Choe EY, et al. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study. Endocrinol Metab (Seoul) 2016; 31:161.</a></li><li><a class="nounderline abstract_t">Vanhove T, Remijsen Q, Kuypers D, Gillard P. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplant Rev (Orlando) 2017; 31:69.</a></li><li><a class="nounderline abstract_t">Strøm Halden TA, Åsberg A, Vik K, et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 2014; 29:926.</a></li><li><a class="nounderline abstract_t">Lane JT, Odegaard DE, Haire CE, et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011; 92:e56.</a></li><li><a class="nounderline abstract_t">Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. Am J Transplant 2014; 14:115.</a></li><li><a class="nounderline abstract_t">Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol 2014; 2014:617638.</a></li><li><a class="nounderline abstract_t">Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34:1431.</a></li><li><a class="nounderline abstract_t">Vest LS, Koraishy FM, Zhang Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant 2018; 32:e13302.</a></li><li><a class="nounderline abstract_t">Stephen J, Anderson-Haag TL, Gustafson S, et al. Metformin use in kidney transplant recipients in the United States: an observational study. Am J Nephrol 2014; 40:546.</a></li><li><a class="nounderline abstract_t">Alnasrallah B, Goh TL, Chan LW, et al. Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. BMC Nephrol 2019; 20:147.</a></li><li><a class="nounderline abstract_t">Kukla A, Hill J, Merzkani M, et al. The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients. Transplant Direct 2020; 6:e524.</a></li><li><a class="nounderline abstract_t">Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999; 25:489.</a></li><li><a class="nounderline abstract_t">Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev 2018; 9:CD011798.</a></li><li><a class="nounderline abstract_t">Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295.</a></li><li><a class="nounderline abstract_t">Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care 2019; 42:1067.</a></li><li><a class="nounderline abstract_t">Rajasekeran H, Kim SJ, Cardella CJ, et al. Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series. Diabetes Care 2017; 40:e75.</a></li><li><a class="nounderline abstract_t">Schwaiger E, Burghart L, Signorini L, et al. Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 2019; 19:907.</a></li><li><a class="nounderline abstract_t">Shah M, Virani Z, Rajput P, Shah B. Efficacy and Safety of Canagliflozin in Kidney Transplant Patients. Indian J Nephrol 2019; 29:278.</a></li><li><a class="nounderline abstract_t">Lim JH, Kwon S, Jeon Y, et al. The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients. Transplantation 2022; 106:e404.</a></li><li><a class="nounderline abstract_t">Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? Ther Adv Endocrinol Metab 2022; 13:20420188221090001.</a></li><li><a class="nounderline abstract_t">Lemke A, Brokmeier HM, Leung SB, et al. Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation. Clin Transplant 2022; 36:e14718.</a></li><li><a class="nounderline abstract_t">Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8:294.</a></li><li><a class="nounderline abstract_t">Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrol Dial Transplant 2014; 29:698.</a></li><li><a class="nounderline abstract_t">Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65:515.</a></li><li><a class="nounderline abstract_t">Woodward RS, Flore MC, Machnicki G, Brennan DC. The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. Value Health 2011; 14:443.</a></li><li><a class="nounderline abstract_t">Rathi M, Rajkumar V, Rao N, et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. Transplant Proc 2015; 47:1158.</a></li><li><a class="nounderline abstract_t">Wissing KM, Abramowicz D, Weekers L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. Am J Transplant 2018; 18:1726.</a></li><li><a class="nounderline abstract_t">Schold JD, Kaplan B, Chumbler NR, et al. Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol 2005; 16:3121.</a></li><li><a class="nounderline abstract_t">Wen X, Casey MJ, Santos AH, et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. Am J Transplant 2016; 16:3202.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77:299.</a></li><li><a class="nounderline abstract_t">Roth D, Milgrom M, Esquenazi V, et al. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47:278.</a></li><li><a class="nounderline abstract_t">Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67:2415.</a></li><li><a class="nounderline abstract_t">Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15:89.</a></li><li><a class="nounderline abstract_t">Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70:SS58.</a></li><li><a class="nounderline abstract_t">Friedman EA, Shyh TP, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5:196.</a></li><li><a class="nounderline abstract_t">Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3:814.</a></li><li><a class="nounderline abstract_t">Wauters RP, Cosio FG, Suarez Fernandez ML, et al. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation 2012; 94:377.</a></li><li><a class="nounderline abstract_t">Cooper L, Oz N, Fishman G, et al. New onset diabetes after kidney transplantation is associated with increased mortality-A retrospective cohort study. Diabetes Metab Res Rev 2017; 33.</a></li><li><a class="nounderline abstract_t">Dienemann T, Fujii N, Li Y, et al. Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. Transpl Int 2016; 29:1017.</a></li><li><a class="nounderline abstract_t">Valderhaug TG, Hjelmesæth J, Hartmann A, et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011; 54:1341.</a></li><li><a class="nounderline abstract_t">Gaynor JJ, Ciancio G, Guerra G, et al. Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant. Diabetologia 2015; 58:334.</a></li><li><a class="nounderline abstract_t">Lindholm A, Albrechtsen D, Frödin L, et al. Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60:451.</a></li><li><a class="nounderline abstract_t">Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9:S16.</a></li><li><a class="nounderline abstract_t">Fernández-Fresnedo G, Escallada R, de Francisco AL, et al. Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc 2003; 35:700.</a></li><li><a class="nounderline abstract_t">Ducloux D, Kazory A, Chalopin JM. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005; 79:438.</a></li><li><a class="nounderline abstract_t">Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.</a></li><li><a class="nounderline abstract_t">Lim WH, Lok CE, Kim SJ, et al. Impact of Pretransplant and New-Onset Diabetes After Transplantation on the Risk of Major Adverse Cardiovascular Events in Kidney Transplant Recipients: A Population-based Cohort Study. Transplantation 2021; 105:2470.</a></li><li><a class="nounderline abstract_t">Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010; 56:1127.</a></li><li><a class="nounderline abstract_t">Klein CL, Brennan DC. The tradeoff between the risks of acute rejection and new-onset diabetes after kidney transplant. Am J Kidney Dis 2010; 56:1026.</a></li><li><a class="nounderline abstract_t">Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998; 65:380.</a></li><li><a class="nounderline abstract_t">Owda AK, Abdallah AH, Haleem A, et al. De novo diabetes mellitus in kidney allografts: nodular sclerosis and diffuse glomerulosclerosis leading to graft failure. Nephrol Dial Transplant 1999; 14:2004.</a></li><li><a class="nounderline abstract_t">Markell M. Clinical impact of posttransplant diabetes mellitus. Transplant Proc 2001; 33:19S.</a></li><li><a class="nounderline abstract_t">Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007; 83:1027.</a></li></ol></div><div id="topicVersionRevision">Topic 7327 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25307034" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720253" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25777999" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The diagnosis of posttransplantation diabetes mellitus: meeting the challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656979" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Glucose metabolism after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30430145" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775942" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559228" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559228" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29407052" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Perioperative Management of Hyperglycemia and Diabetes in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29407052" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Perioperative Management of Hyperglycemia and Diabetes in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/382510" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diabetes mellitus--a more-common-than-believed complication of renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023151" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12603213" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diabetes mellitus after kidney transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168956" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667949" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17627237" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249743" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17359512" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431233" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27547871" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25626344" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : OPTN/SRTR 2013 Annual Data Report: kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811893" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : OPTN/SRTR 2017 Annual Data Report: Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752315" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538615" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical evolution of post-transplant diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9381545" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12499885" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11274282" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27871759" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936569" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579527" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28376034" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rapid Discontinuation of Prednisone in Kidney Transplant Recipients: 15-Year Outcomes From the University of Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633374" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18309002" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17198258" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk factors for development of new-onset diabetes mellitus after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476489" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Development of diabetes mellitus following kidney transplantation: a Canadian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242885" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859533" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940032" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Tacrolimus and posttransplant diabetes mellitus in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094377" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Reduced exposure to calcineurin inhibitors in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699459" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30450457" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726827" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26717860" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401009" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk for posttransplant Diabetes mellitus with current immunosuppressive medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31941840" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tacrolimus- and sirolimus-induced humanβcell dysfunction is reversible and preventable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459544" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385422" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sirolimus is associated with new-onset diabetes in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25146383" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21336240" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327329" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558559" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999231" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Continuous glucose monitoring after kidney transplantation in non-diabetic patients: early hyperglycaemia is frequent and may herald post-transplantation diabetes mellitus and graft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307061" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12234317" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Patient survival after renal transplantation: IV. Impact of post-transplant diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477217" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961026" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579520" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162192" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16869798" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168375" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10812121" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11723094" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15338129" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/527222" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hypomagnesaemia in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3907234" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serum and erythrocyte magnesium levels in type I and type II diabetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8505087" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Magnesium deficiency produces insulin resistance and increased thromboxane synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807442" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Insulin resistance and hypomagnesaemia: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624560" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449610" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24686469" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Relation between pretransplant magnesemia and the risk of new onset diabetes after transplantation within the first year of kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970568" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24609888" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Lower magnesium level associated with new-onset diabetes and pre-diabetes after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970569" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Elevated serum gamma-glutamyltransferase and hypomagnesemia are not related with new-onset diabetes after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480976" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Post-transplant hyperglycaemia: a study of risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552513" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Demographics and trends in overweight and obesity in patients at time of kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1989201" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17220788" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10528694" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Insulin resistance in patients with adult polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344369" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673321" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27184299" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The Risk for New-Onset Diabetes Mellitus after Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32548247" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Autosomal Dominant Polycystic Kidney Disease Is a Risk Factor for Posttransplantation Diabetes Mellitus: An Updated Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26789123" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A HuGE Review and Meta-Analyses of Genetic Associations in New Onset Diabetes after Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28435278" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Genetic factors in pathogenesis of diabetes mellitus after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22377791" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23902993" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23279163" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15877787" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Guidelines for the treatment and management of new-onset diabetes after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042775" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Diagnosis and classification of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19502545" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559241" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19429873" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23164767" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23074234" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27875061" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Simplified transition algorithm from intravenous to subcutaneous insulin in nondiabetic cardiac surgery patients with stress hyperglycemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35690958" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343119" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Early basal insulin therapy decreases new-onset diabetes after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29961246" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492541" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : HOSPITAL INSULIN PROTOCOL AIMS FOR GLUCOSE CONTROL IN GLUCOCORTICOID-INDUCED HYPERGLYCEMIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21411550" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31568390" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18301331" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21564529" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Should metformin be our antiglycemic agent of choice post-transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28238223" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16539642" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Repaglinide in the management of new-onset diabetes mellitus after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26754588" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27665059" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24452849" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067216" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24279801" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24817885" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617112" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Use of metformin in the setting of mild-to-moderate renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29851159" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25613554" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Metformin use in kidney transplant recipients in the United States: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31035960" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32095510" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10467625" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Drug selection and the management of corticosteroid-related diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246878" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990260" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30862658" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28416475" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30585690" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31423063" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Efficacy and Safety of Canagliflozin in Kidney Transplant Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35768908" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35450095" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35593882" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9048349" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24009292" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500626" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21315636" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26036543" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29337426" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135772" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27137884" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19847156" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645712" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15882287" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11264633" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152233" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Impact and management of posttransplant diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3893130" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Posttransplant diabetes in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322046" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22820698" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28731619" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : New onset diabetes after kidney transplantation is associated with increased mortality-A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27284760" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21409415" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : The association of early post-transplant glucose levels with long-term mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361829" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7676492" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443763" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Epidemiology of cardiovascular disease in chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12644099" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729170" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15615820" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Incidence and predictors of myocardial infarction after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33560726" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Impact of Pretransplant and New-Onset Diabetes After Transplantation on the Risk of Major Adverse Cardiovascular Events in Kidney Transplant Recipients: A Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934793" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21094914" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : The tradeoff between the risks of acute rejection and new-onset diabetes after kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484755" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10462285" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : De novo diabetes mellitus in kidney allografts: nodular sclerosis and diffuse glomerulosclerosis leading to graft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11498200" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Clinical impact of posttransplant diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452891" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
